You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
AstraZeneca
Dow
McKesson
Colorcon

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,211,889


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,211,889 protect, and when does it expire?

Patent 8,211,889 protects TAVALISSE and is included in one NDA.

This patent has thirty-one patent family members in twenty-four countries.

Summary for Patent: 8,211,889
Title:Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Inventor(s): Singh; Rajinder (Belmont, CA), Bhamidipati; Somasekhar (Foster City, CA), Sun; Thomas (Fremont, CA), Stella; Valentino J. (Lawrence, KS)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:13/349,194
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,211,889

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,211,889

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 451381   Start Trial
Australia 2006206458   Start Trial
Brazil PI0606318   Start Trial
Canada 2591948   Start Trial
China 101115761   Start Trial
Cyprus 1109888   Start Trial
Germany 602006010979   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Merck
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.